

16th July, 2018

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Scrip Code: NSE - AJANTPHARM EQ

Sub: News Clarification

Kind Attn.: Mr. Sandeep Dhamal

Dear Sir,

With reference to your mail seeking clarification on the attached news item, we have to clarify as under:

1. There is no action against Ajanta Pharma Ltd. from the office of Drug Controller General of India and we refute the allegations made against the company in the said article.
2. The action is taken against M/s. Safetab Life Sciences, who is the manufacturer of drugs. We are only marketing the drugs.
3. There is no impact of this article on the Company as Ajanta Pharma Ltd. is fully compliant with all the applicable regulatory requirements.
4. Since this would have no bearing on the performance or operations of the Company, the same is not required to be disclosed under Regulation 30 of the Listing Regulations, hence not disclosed.

We hope above clarifies the position.

Thanking You,

Yours faithfully,



GAURANG SHAH
AVP - Legal &
Company Secretary